Initiation of GDMT Therapy in Patients Discharged Post AHF – What are the Guardrails?

This section presents a concise, high-yield summary of the video’s core content, designed as a quick reference for Healthcare Professionals (HCPs).

Note: This content was developed by our editorial team and was not reviewed or endorsed by the video speaker.

Q1: Why is acute and worsening heart failure distinguished from chronic heart failure?
A: It represents an acutely deteriorated clinical state marked by heightened vulnerability to adverse events, functional decline, and recurrent exacerbations.[1,2] 

Q2: Why is the transition period after hospitalisation considered strategically important in heart failure?
A: Event rates during the first six to twelve weeks are disproportionately high. This period combines clinical instability, residual congestion, treatment gaps, and undertitration of guideline-directed therapy. It therefore functions as a clinically actionable window during which optimisation of foundational therapy may alter longer-term outcomes. [10,11] 

Q3: What distinguishes the STRONG-HF model from conventional post-discharge care?
A: It replaces gradual outpatient titration with rapid initiation, structured intensification, laboratory surveillance, NT-proBNP monitoring, congestion assessment, and scheduled follow-up visits. This framework demonstrated reductions in death and rehospitalisation at 180 days. [3,4] 

Q4: How should NT-proBNP be incorporated into therapy optimisation?
A: Rising NT-proBNP values during the first week after discharge may indicate the need for prioritised decongestion before titration, whereas stable or declining values support more aggressive optimisation of GDMT. Its role in stratifying patients during this vulnerable period was a central theme of the session. [3]

Q5: Are there practical considerations that limit translation of trial protocols into routine care?
A: Laboratory monitoring, nursing coordination, pharmacy collaboration, and early follow-up appointments are required to maintain safety and adherence. Experience from RALES illustrated that without structured safety surveillance, real-world implementation can diverge from trial results and produce unintended harm. [12,13,14] 

Q6: What insights were emphasised from the Taiwan registries and HF-PAC programme?
A: Earlier registries in Taiwan showed low use of guideline-directed medical therapy and limited titration after discharge. Subsequent HF-PAC implementation and updated registry work demonstrated increases in GDMT penetration and improvements in outcomes, supporting the feasibility of adopting STRONG-HF principles at a population level. [7] 

Q7: How do contemporary guidelines position early initiation and titration of GDMT?
A: The 2023 ESC HF guideline focused update recommends intensive initiation and up-titration of GDMT during the first six weeks after hospitalisation for acute heart failure, indicating formal guideline endorsement of the transition-phase optimisation concept. [5,6]